This study investigates metastatic pancreatic ductal adenocarcinoma. It compares the effects of an investigational medication combined with chemotherapy to a placebo with chemotherapy.
The purpose of this study is to evaluate the safety and effectiveness of the investigational medication in treating the condition. The study focuses on understanding how well the investigational medication works and how safe it is for participants.
- Who can participate: Adults aged 18 to 75 years with metastatic pancreatic ductal adenocarcinoma who have not received prior systemic treatment for their cancer can join.
- Study details: Participants will receive either an investigational medication with chemotherapy or a placebo with chemotherapy. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.